Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in High-risk Multiple Myeloma
NCT06207799Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2024
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year, Sustained Minimal Residual Disease-negative Complete Response at 1 year and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06207799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207799.